SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report: May 7, 2002
-------------------------------
(Date of earliest event reported)
FOUNTAIN PHARMACEUTICALS, INC.
-----------------------------------------------------
Exact name of registrant as specified in its charter
Delaware 0-18399 62-1386759
------------------------------ -------------------- -----------------
State of other jurisdiction of Commission File No. I.R.S. Employer
incorporation or organization ID No.
505 South Westland Avenue, Suite D, Tampa, Florida 33606
--------------------------------------------------------
(Address of principal executive offices)
Registrant's telephone number, including area code: (813) 248-0086
N/A
-----------------------------------------------------------
(Former name or former address if changed since last report)
ITEM 5. OTHER EVENTS
EXCEPT AS EXPRESSLY INDICATED OR UNLESS THE CONTEXT OTHERWISE REQUIRES,
"FOUNTAIN PHARMACEUTICALS," "WE," "OUR," OR "US" MEANS FOUNTAIN PHARMACEUTICALS,
INC., A DELAWARE CORPORATION.
On May 7, 2002, we announced that in response to comments from the
Securities and Exchange Commission ("SEC") the corporate actions described in
the Information Statement first filed on April 12, 2002, amended on April 24,
2002, mailed on or about April 25, 2002 and refiled as a Preliminary Schedule
14C on April 30, 2002, will not be taken until 20 days after the SEC has
completed its review process of the Company's amended Preliminary Schedule 14C
and a Definitive Information Statement is filed and mailed to shareholders. A
copy of the press release announcing the foregoing is attached as Exhibit 99.1
to this Form 8-K and is incorporated by reference hereto.
ITEM 7. EXHIBITS
99.1 Press Release issued by Fountain Pharmaceuticals, Inc. on
May 7, 2002 announcing that the Company will not take the
corporate actions described in the Information Statement
mailed to its shareholders.
Pursuant to the requirements of the Securities Exchange Act of 1934,
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
FOUNTAIN PHARMACEUTICALS, INC.
By: /s/ Brendon K. Rennert
---------------------------------
Brendon K. Rennert, President
Dated: May 7, 2002
2